Printer Friendly

CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

 CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC
 FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
 ANAHEIM, Calif., Oct. 26 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) announced today at the annual meeting of the Society for Neuroscience in Anaheim, Calif. results of preclinical studies of a novel class of compounds for the treatment of neurodegenerative diseases. Michael E. Lewis, Ph.D., Cephalon's senior director of Scientific Affairs presented data that K252a and analogs can promote the survival of neurons that are compromised in injury or disease. These proprietary compounds may represent the first class of small organic molecules to exert direct neurotrophic actions similar to those observed with large proteins such as CNTF or NGF.
 "The advantage of these small molecules is that they are stable and cross the blood-brain barrier," commented Dr. Lewis, "unlike large neurotrophic proteins which present significant delivery limitations in the treatment of diseases of the central nervous system."
 In June, Cephalon entered an exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd., of Tokyo to collaborate on the development of derivatives of the K252a small neurotrophic molecule for the treatment of neurodegenerative disorders. Patents have been issued worldwide on the novel composition of all these structures, including derivatives and the manufacturing process.
 During this week's Neuroscience meeting, Cephalon researchers will also present data from animal studies demonstrating that insulin-like growth factor-1 (IGF-1) enhances recovery of motor function after traumatic nerve injury. Myotrophin(TM), a recombinant human form of IGF-1 being developed by Cephalon, has previously demonstrated in preclinical testing the ability to enhance motor neuron survival and to induce neuronal sprouting and nerve regeneration in models of neurodegenerative disease. Cephalon is developing Myotrophin for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease) and peripheral neuropathy.
 "Our research programs at Cephalon cover a broad spectrum of therapeutic compounds for neurological diseases," indicated Dr. Frank Baldino, Jr., president and chief executive officer of Cephalon. "With ten presentations at this week's Neuroscience meeting the strength of our research and development programs is demonstrated across many therapeutic areas, including Alzheimer's disease, ALS and peripheral neuropathy."
 Cephalon, Inc. focuses on the development of products to treat neurodegenerative diseases. These diseases are characterized by the death of neurons, the specialized conducting cells of the nervous system. The company has concentrated its research programs on the prevention of neural death in several disorders, including ALS, Alzheimer's disease, head and spinal cord injuries, stroke, peripheral neuropathy and retinopathy.
 -0- 10/26/92
 /CONTACT: Nicole Vitullo, director of corporate communications of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-505-1919, for Cephalon/
 (CEPH) CO: Cephalon, Inc. ST: California IN: MTC SU:


TS-LR -- NY027 -- 4643 10/26/92 10:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 26, 1992
Words:446
Previous Article:BG&E RECOGNIZED FOR ITS COMMITMENT TO SAFETY BELT USE
Next Article:ATRIX INTERNATIONAL ANNOUNCES FIRST QUARTER RESULTS
Topics:


Related Articles
CEPHALON, INC.'S MYOTROPHIN(TM) DEMONSTRATES SAFETY IN PHASE I TRIALS
CEPHALON INITIATES EUROPEAN PHASE II/III CLINICAL TRIAL OF MYOTROPHIN(TM)
MYOTROPHIN CLINICAL TRIAL DATA TO BE PRESENTED AT MEETINGS IN DUBLIN, IRELAND, AND WASHINGTON, DC
Guilford Pharmaceuticals Develops First Novel Oral Compounds Which Demonstrate Regenerative Activity In Animal Models of Parkinson's Disease
NeoTherapeutics, Inc. Research Findings Support Upcoming Clinical Trials for Novel Therapeutic for the Treatment of Alzheimer's Disease
NeoTherapeutics' New Class of Alzheimer's Drug Begins Patient Trials in Canada
NeoTherapeutics' Files Investigational New Drug Application with FDA For Lead Compound, AIT-082
NeoTherapeutics Provides Update on Canadian Clinical Trial
NeoTherapeutics to Begin Clinical Trials in U.S. on Lead Compound, AIT-082; Trials Will be Conducted by the Alzheimer's Disease Cooperative Study
NeoTherapeutics Reports Memory Improvement of Alzheimer's Patients in Clinical Trial

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters